Breast Cancer Therapies
Tucatinib
BPT-1207 · Tablet
What is it used for?
Targets HER2 signaling. Used with trastuzumab and capecitabine for previously treated advanced HER2-positive breast cancer, including brain metastases. The supplier sheet says HER2-negative; that is incorrect for this indication.
- Dosage form
- Tablet
- Listed strengths
- 150 mg
- Listed pack size
- 30's
- Mechanism
- HER2-directed kinase inhibitor
Specifications supplied in the Everest product list; formulation, pack configuration, availability and local authorization require confirmation. These medicines are not for self-medication.
Clinical use overview
- Previously treated HER2-positive advanced breast cancer, in a specified combination
Important information
Educational information about the active ingredient, not a treatment recommendation or a claim that Beptide's presentation is approved. Approved uses differ by country and product. Cancer medicines require specialist assessment; biomarkers, stage, previous treatments and combinations can determine eligibility.
FDA prescribing information
